Sarcomas are tumors of mesenchymal origin that make up a heterogeneous group of more than 80 tumors [1]. These can be broadly categorized into bone sarcomas including osteosarcoma, chondrosarcoma, multiple myeloma, Ewing sarcoma and soft tissue sarcomas comprising liposarcoma, fibrosarcoma, leiomyosarcoma, synovial sarcoma, rhabdomyosarcoma, pleomorphic sarcoma, malignant nerve sheath tumor & spindle cell sarcoma [2]. Epidemiological statistics show that bone sarcomas account for a total percentage of 0.2% of all malignancies with an incidence rate of 0.9 per 100000 people, annually [3]. Giant cell tumors are although non-cancerous but very aggressive locally, typically involving the metaphysis of long bones [4].
Historically, amputation was being adapted solely as the treatment of these musculoskeletal tumors to achieve sufficient margins. However, over the past years due to the advancement in diagnostic imaging modalities, surgical procedures and adjuvant therapies, limb salvage surgeries have now become the new treatment paradigm. The primary aim of the management is to control the local spread of the tumor with minimal complications, preserve the surrounding neurovascular and musculoskeletal structures, reconstruct the limb and restore its function [5]. Limb salvage surgeries thereby reduce morbidity and raise the quality of life. Considering the new treatment modalities, now amputation is only reserved for the cases in which tumors are extending beyond the compartment boundaries when there is extensive neurovascular damage or failure of the limb-sparing procedure [6]. Previously considered absolute contraindications to limb salvage surgery i.e., pathologic fractures and neurovascular bundle involvement are now considered relative contraindications [7, 8]. Limb sparing procedures include wide margin excision of the tumor in case of soft tissue tumor whereas in the case of bone sarcoma, the limb salvage procedure requires wide margin excision of the tumor, removal of the diseased bone and reconstruction of the limb via using grafts (allografts or autografts) or endoprosthesis [9].
Limb salvage surgeries have better cosmetic results and more functional outcomes. Tumor surgery, chemotherapy, radiation, and imaging technologies have all improved considerably over the past few years and due to this reason, the number of limb sarcoma survivorship studies (LSS) has increased [10] There is research on complications of limb salvage surgeries in patients with malignancies from other world regions; however, data from our region is sparse [11, 12, 13].
Complications of limb salvage surgery in a well-equipped hospital in Pakistan and what risk factors are likely to be associated with these complications. A higher complication rate would warrant a change in indications and surgical technique.
The primary objective of our study was to determine the incidence of early complications occurring within the first thirty days in patients who underwent limb salvage surgery. The secondary objective was to assess the association of these complications with patient-related factors, surgical modality, tumor characteristics and neoadjuvant therapy.
This prospective study was conducted at the Section of Orthopedics, Department of Surgery, Aga khan hospital, Karachi. Appropriate approvals were obtained from the Hospital Ethical Review Committee.
All patients with primary bone or soft tissue sarcomas and aggressive giant cell tumors of the extremities who underwent limb salvage surgery from February 2020 to December 2021 were included in this study. Data was collected on follow-up visits of all these patients by a senior orthopaedic surgeon and a dedicated orthopedic research officer over thirty days. Patients who underwent only curettage for high-grade giant cell tumors and those who were lost to follow-up were excluded from this study.
Patient demographics, prior comorbid conditions, tumor characteristics, surgical modalities and the complications occurring in early post-operative were extracted as variables of interest. The data were assessed for local and systemic complications. A cut-off of 30 days was used to calculate the incidence of these post-procedural complications.
After the data was collected, it was compiled and analyzed by using SPSS (Statistical Package for the Social Sciences). A p-value of <0.05 was considered significant throughout the study. Quantitative variables such as age were reported as mean and standard deviation. Qualitative variables such as gender and complications were mentioned as frequency and percentage. The association of qualitative variables with the postoperative complications were assessed by using the chi-square/fisher exact test. This study has been registered in the research registry, the number is researchregistry4695 and it is being reported in line with STROCSS research reporting guidelines [14].
The mean age of our patients was 39.90 years (SD = 18.98) ranging from 4 years to 74 years. Of these patients, 41 were males and 19 were females. Twenty-one out of 60 patients had prior comorbid conditions accounting for 35%, with 25 per cent of patients having high blood pressure, 20% having diabetes, and 6.7% having a body mass index (BMI) greater than 25, compared to 65% of patients who did not have any comorbid condition. Family history of tumors was found to be positive in 13.3% of cases.
Twenty-five patients had Bone tumors, while soft tissue tumors were present in 35 patients. The lower limb was the most common site of tumor involvement; there were 38 patients with lower limb tumors followed by upper limb tumors in 19 patients and pelvic tumors in 3 patients.
The final diagnosis in 11 patients was myxofibrosarcoma, 9 patients had osteosarcoma, 7 had Ewing’s sarcoma and liposarcoma each and 5 had spindle cell sarcoma (Table 1).
Table 1
Types of Tumors.
TUMOR TYPES | FREQUENCY- n (%) |
---|---|
Myxofibrosarcoma | 11 |
Osteosarcoma | 9 |
Ewing sarcoma | 7 |
Liposarcoma | 7 |
Spindle cell sarcoma | 5 |
Synovial sarcoma | 4 |
Metastatic tumours | 3 |
Giant cell tumour | 3 |
Pleomorphic sarcoma | 3 |
Chondrosarcoma | 2 |
Malignant nerve sheath tumor | 1 |
Leiomyosarcoma | 1 |
Clear cell sarcoma | 1 |
B cell lymphoma | 1 |
Malignant melanoma | 1 |
Squamous cell carcinoma | 1 |
Total | 60 |
Out of these 60 subjects, 23 underwent wide margin excision, 16 underwent WME + flap coverage, 14 underwent WME + endoprosthesis and 4, 2 and 1 underwent WME+ autograft reconstruction, hemipelvectomy and WME + fresh allograft reconstruction respectively. A total of 36 patients received neoadjuvant therapy in the form of chemotherapy/radiotherapy or a combination of both.
The total number of patients who experienced any complication following surgery was found to be 13. As shown in Table 2, most of these postoperative complications were wound related, 4 patients had deep infection followed by delayed wound healing in 3 patients and 1 patient experienced superficial site infection. Wound dehiscence occurred in one patient. One patient experienced a neurological complication of foot drop. On the twentieth postoperative day, 1 patient had disruption of pseudoarthrosis of the shoulder joint and similarly, 1 patient experienced postoperative hematoma collection on day 16. No systemic pulmonary or neurological complications were noted.
Table 2
Early Complication with 30 days of surgery.
COMPLICATIONS | n (%) |
---|---|
Deep infection | 4 (6.7%) |
Delayed wound healing | 3 (5%) |
Superficial site infection | 1 (1.7%) |
Wound dehiscence | 1 (1.7%) |
Neurovascular complications | 1 (1.7%) |
Disruption of pseudoarthrosis | 1 (1.7%) |
Hematoma collection | 1 (1.7%) |
Total complications | 13 (21.7) |
We studied the association between various parameters using chi-square tests and found no significant statistical association between early complications and gender, prior comorbid conditions, type of tumor, location of tumor and provision of neoadjuvant therapy (p-value > 0.05) Table 3.
Table 3
Association of postoperative complications with patient-related factors and tumor characteristics.
FREQUENCY – n (%) | p-value | |
---|---|---|
Gender | 0.552 | |
Male | 8 (19.5%) | |
Female | 5 (26.3%) | |
Comorbidities | ||
Yes | 6 (28.6%) | 0.341 |
No | 7 (17.9%) | |
Type of tumor | ||
Bone tumor | 6 (24.0%) | 0.711 |
Soft tissue | 7 (20.0%) | |
Anatomical location of the tumor | 0.392 | |
Upper limb | 6 (31.6%) | |
Lower limb | 7 (18.4%) | |
Pelvis | 0 | |
Neoadjuvant therapy | ||
Yes | 10 (27.8%) | 0.159 |
No | 3 (12.5%) | |
Although limb salvage surgical techniques have advanced significantly in recent years, early postoperative complications continue to be a major cause of morbidity. According to our study, 21.7% of patients experienced complications in the first thirty days after surgery. In a retrospective study by Gallaway, Kathryn E et al. overall, 14.0% of patients reported at least one complication within the first 30 days after surgery for sarcoma of the limbs, out of which the most frequent complication was surgical site infection (superficial and deep both) making up 4% and 3% of the total patients followed by wound dehiscence which made up 1.8% [15]. These results are quite similar to our study in which out of 60 patients 4 had deep site infection and 1 had superficial site infection making up 6.7% and 1.7% respectively, and wound dehiscence was observed in one patient accounting for 1.7%.
Gharedhagi, Muhammad et al. in a retrospective cohort study including 40 patients reported a complication rate of 45.4% following limb salvage surgery which is quite higher than our study. This difference may be due to the longer duration of follow-up (24 months) as compared to our study which was 30 days only [16] and for such reason long-term complications such as allograft nonunion, prosthesis fracture and loosening, allograft fracture and implant failure were not reported in our study. Moore et al. in a retrospective study including 256 cases reported a 17.6% rate of major wound complications occurring in a median of 21.5 days after soft tissue sarcoma resection [17].
Additionally, a retrospective study by Yoichi Kaneuchi et al, reported that out of total of 65 patients aged <10 years with primary osteosarcoma who underwent limb salvage surgery, 46% faced postoperative complications out of which 24 patients developed early complications (<6 months) [18]. In our study, only 3 out of 60 patients were aged <10 years out of which 1 patient developed superficial site infection. However, the quoted study included only patients who were less than 10 years of age and in our study patients of all age groups were included which could account for the difference observed in this study.
Patient demographics including age, gender and prior comorbid conditions, type and location of the tumor, type of procedure and the provision of neoadjuvant or adjuvant therapies are all proposed risk factors for the occurrence of postoperative complications. A higher incidence of wound complications was linked to patients’ comorbidities in the previous literature [17]. However, according to our findings, there is no significant association between the incidence of postoperative complications and patient demographics (p-value > 0.005).
Korah et al. concluded that the anatomical location of the tumor was one of the most important risk factors for postoperative wound complications. Anatomical differences, such as the proximity of critical neurovascular structures and joint spaces, complicate surgical resection. Concerning the location of sarcomas, previous literature has shown that wound complications were more common in instances involving the lower extremities [19]. In addition to being rare, pelvic sarcomas arise close to the neurovascular structures and viscera thereby posing a great challenge for their adequate resection [20]. On the contrary, according to our findings, most of the patients with upper limb sarcomas experienced early postoperative complications and the association between the anatomical location of the tumor and the occurrence of postoperative complications was statistically insignificant which may be because our study is limited by small sample size (p-value = 0.392).
Neoadjuvant therapy is commonly used as an adjunct to surgery for high-grade tumors. Radiotherapy alone or radiotherapy along with chemotherapy can be utilized in combination with surgery to combat large, aggressive tumors that are difficult to remove. However, according to the previous literature preoperative radiation is linked to a higher risk of wound complications [17]. According to a study by Sullivan et al. the patients who receive preoperative radiotherapy are more likely to develop postoperative wound complications as compared to those who received radiation after surgery, so the size and location of the tumor, timing of surgery and duration of radiotherapy should be taken into account when making management decisions for a given patient [21]. Individuals with weakened immune systems, geriatric populations or patients with massive tumors are particularly susceptible in this regard [22]. Neoadjuvant chemotherapy is a notion that is still up for debate [23] and the majority of clinicians still don’t accept it. A study by Gronhi et al. concluded that concomitant administration of chemotherapy and radiation therapy not only doubles the risk of high-grade thrombocytopenia but also one out of six patients experience postoperative wound complications [24]. However, there was an insignificant statistical association between the neoadjuvant therapy and the occurrence of complications according to our findings.
The study’s limitations include the fact that it was conducted in a single location and the sample size was small which could be attributable to the low incidence of sarcomas in our population, implying that the findings cannot be generalized to the entire population. Designing multi-centred research studies to achieve a larger sample size will improve the accuracy and validity of these results.
The most frequently occurring early complications in the first month after limb salvage surgeries are wound-related and the incidence of these complications is independent of the proposed risk factors. However, due to cultural and financial constraints in our country, a lesser number of patients seek medical advice hence the incidence of these tumours reported is very low. Multicenter studies should be conducted to achieve a larger sample size so that occurrence of postoperative complications and their association with proposed risk factors can be studied in a better way.
Ethical committee approval was sought before the commencement of this study.
The authors have no competing interests to declare.
Z. Ali was involved in manuscript writing, data collection and data analysis. J. Saeed was involved in critical review of the manuscript. M. Umer was involved in the study conception and supervision.
Not commissioned, externally peer-reviewed.
Fletcher C. Pathology and genetics of tumors of soft tissue and bone. World health organization classification of tumors. 2002; 4: 35–46.
Skubitz KM, D’Adamo DR, (eds.) Sarcoma. Mayo Clinic Proceedings; 2007. Elsevier. DOI: https://doi.org/10.4065/82.11.1409
Franchi A. Epidemiology and classification of bone tumors. Clinical Cases in mineral and bone metabolism. 2012; 9(2): 92.
van der Heijden L, Dijkstra PD, van de Sande MA, Kroep JR, Nout RA, van Rijswijk CS, Bovée JV, Hogendoorn PC, Gelderblom H. The clinical approach toward giant cell tumor of bone. Oncologist. 2014 May; 19(5): 550–61. Epub 2014 Apr 9. PMID: 24718514; PMCID: PMC4012970. DOI: https://doi.org/10.1634/theoncologist.2013-0432
Kadam D. Limb salvage surgery. Indian Journal of Plastic Surgery: Official Publication of the Association of Plastic Surgeons of India. 2013; 46(2): 265. DOI: https://doi.org/10.4103/0970-0358.118603
Jauregui JJ, Nadarajah V, Munn J, Pivec R, Kapadia BH, Lerman DM, et al. Limb salvage versus amputation in conventional appendicular osteosarcoma: a systematic review. Indian journal of surgical oncology. 2018; 9(2): 232–40. DOI: https://doi.org/10.1007/s13193-018-0725-y
van Houdt WJ, Griffin AM, Wunder JS, Ferguson PC. Oncologic outcome and quality of life after hindquarter amputation for sarcoma: is it worth it? Annals of surgical oncology. 2018; 25(2): 378–86. DOI: https://doi.org/10.1245/s10434-017-5806-6
Smith HG, Thomas JM, Smith MJ, Hayes AJ, Strauss DC. Major amputations for extremity soft-tissue sarcoma. Annals of surgical oncology. 2018; 25(2): 387–93. DOI: https://doi.org/10.1245/s10434-017-5895-2
Endo M, Lin PP. Surgical margins in the management of extremity soft tissue sarcoma. China Clinical Oncology. 2018; 7(4): 37. DOI: https://doi.org/10.21037/cco.2018.08.10
Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. New England journal of medicine. 2005; 353(7): 701–11. DOI: https://doi.org/10.1056/NEJMra041866
Erstad DJ, Ready J, Abraham J, Ferrone ML, Bertagnolli MM, Baldini EH, et al. Amputation for extremity sarcoma: contemporary indications and outcomes. Annals of surgical oncology. 2018; 25(2): 394–403. DOI: https://doi.org/10.1245/s10434-017-6240-5
Jawad MU, Haleem AA, Scully SP. Malignant sarcoma of the pelvic bones: treatment outcomes and prognostic factors vary by histopathology. Cancer. 2011; 117(7): 1529–41. DOI: https://doi.org/10.1002/cncr.25684
Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European journal of cancer. 2019; 109: 36–50. DOI: https://doi.org/10.1016/j.ejca.2018.11.027
Mathew G, Agha R, for the STROCSS Group. STROCSS 2021: Strengthening the Reporting of cohort, cross-sectional and case-control studies in Surgery. International Journal of Surgery. 2021; 96: 106165. DOI: https://doi.org/10.1016/j.ijsu.2021.106165
Gallaway KE, Ahn J, Callan AK. Thirty-day outcomes after surgery for primary sarcomas of the extremities: an analysis of the NSQIP database. Journal of Oncology. 2020; 2020. DOI: https://doi.org/10.1155/2020/7282846
Gharehdaghi M, Hassani M, Parsa A, Omidikashani F, Jarrahi L, Hosseini R. Short term complications and functional results of sarcoma limb salvage surgeries. Archives of Bone and Joint Surgery. 2019; 7(2): 161.
Moore J, Isler M, Barry J, Mottard S. Major wound complication risk factors following soft tissue sarcoma resection. European Journal of Surgical Oncology (EJSO). 2014; 40(12): 1671–6. DOI: https://doi.org/10.1016/j.ejso.2014.10.045
Kaneuchi Y, Yoshida S, Fujiwara T, Evans S, Abudu A. Limb salvage surgery has a higher complication rate than amputation but is still beneficial for patients younger than 10 years old with osteosarcoma of an extremity. Journal of Pediatric Surgery. 2022. DOI: https://doi.org/10.1016/j.jpedsurg.2022.04.001
Korah MP, Deyrup AT, Monson DK, Oskouei SV, Weiss SW, Landry J, et al. Anatomic tumor location influences the success of contemporary limb-sparing surgery and radiation among adults with soft tissue sarcomas of the extremities. International Journal of Radiation Oncology* Biology* Physics. 2012; 82(2): 933–9. DOI: https://doi.org/10.1016/j.ijrobp.2010.11.020
Angelini A, Drago G, Trovarelli G, Calabrò T, Ruggieri P. Infection after surgical resection for pelvic bone tumors: an analysis of 270 patients from one institution. Clinical Orthopaedics and Related Research®. 2014; 472(1): 349–59. DOI: https://doi.org/10.1007/s11999-013-3250-x
O›Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. The Lancet. 2002; 359(9325): 2235–41. DOI: https://doi.org/10.1016/S0140-6736(02)09292-9
Suit HD, Mankin HJ, Wood WC, Proppe KH. Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. Cancer. 1985; 55(11): 2659–67. DOI: https://doi.org/10.1002/1097-0142(19850601)55:11<2659::AID-CNCR2820551122>3.0.CO;2-Q
Gortzak E, Azzarelli A, Buesa J, Bramwell V, Van Coevorden F, Van Geel A, et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. European Journal of Cancer. 2001; 37(9): 1096–103. DOI: https://doi.org/10.1016/S0959-8049(01)00083-1
Pasquali S, Gronchi A. Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. Therapeutic advances in medical oncology. 2017; 9(6): 415–29. DOI: https://doi.org/10.1177/1758834017705588